SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 51,884 Shares

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 51,884 shares of SiBone stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $19.46, for a total transaction of $1,009,662.64. Following the completion of the transaction, the chief executive officer owned 321,386 shares of the company’s stock, valued at $6,254,171.56. This trade represents a 13.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Laura Francis also recently made the following trade(s):

• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $78,538.46.

SiBone Price Performance

NASDAQ SIBN traded up $0.48 during trading hours on Friday, reaching $19.96. 1,290,316 shares of the company’s stock were exchanged, compared to its average volume of 620,561. The firm has a fifty day moving average of $17.40 and a 200-day moving average of $15.30. SiBone has a one year low of $11.48 and a one year high of $21.89. The stock has a market cap of $885.21 million, a PE ratio of -58.71 and a beta of 0.66. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.06. The firm had revenue of $56.01 million during the quarter, compared to the consensus estimate of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. On average, equities research analysts predict that SiBone will post -0.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SiBone

Several large investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in SiBone by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after purchasing an additional 1,053 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of SiBone during the 1st quarter worth approximately $225,000. Goldman Sachs Group Inc. raised its stake in shares of SiBone by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock worth $5,328,000 after buying an additional 83,919 shares during the last quarter. Jane Street Group LLC acquired a new position in SiBone in the first quarter valued at approximately $1,818,000. Finally, Legal & General Group Plc boosted its stake in SiBone by 16.1% in the second quarter. Legal & General Group Plc now owns 42,403 shares of the company’s stock valued at $798,000 after acquiring an additional 5,888 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on SIBN shares. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. UBS Group raised their price objective on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Truist Financial reaffirmed a “buy” rating and issued a $23.00 target price (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. Finally, TD Cowen boosted their target price on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.17.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.